DOP2017000055A - Tratamientos médicos a base de anamorelina - Google Patents

Tratamientos médicos a base de anamorelina

Info

Publication number
DOP2017000055A
DOP2017000055A DO2017000055A DO2017000055A DOP2017000055A DO P2017000055 A DOP2017000055 A DO P2017000055A DO 2017000055 A DO2017000055 A DO 2017000055A DO 2017000055 A DO2017000055 A DO 2017000055A DO P2017000055 A DOP2017000055 A DO P2017000055A
Authority
DO
Dominican Republic
Prior art keywords
anamorelin
anamoreline
medical treatments
based medical
cancer
Prior art date
Application number
DO2017000055A
Other languages
English (en)
Inventor
Mann William
Friend John
Polvino William
Allen Suzan
Lu Ming
Duus Elizabeth
Giorgino Ruben
Baroni Enrico
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2017000055(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of DOP2017000055A publication Critical patent/DOP2017000055A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Se describen procedimientos para la fabricación de medicamentos útiles para el tratamiento de afecciones relacionadas con el cáncer usando anamorelina. La modalidad principal se relaciona con la afección única de pacientes que la definen mediante el tratamiento de la caquexia en un paciente humano con cáncer, que comprende el uso de una cantidad terapéuticamente efectiva de anamorelina durante un período terapéuticamente efectivo, y la sorprendente capacidad observada de la anamorelina de aumentar la masa corporal magra de esta población.
DO2017000055A 2014-09-04 2017-03-03 Tratamientos médicos a base de anamorelina DOP2017000055A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04

Publications (1)

Publication Number Publication Date
DOP2017000055A true DOP2017000055A (es) 2017-08-15

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000055A DOP2017000055A (es) 2014-09-04 2017-03-03 Tratamientos médicos a base de anamorelina

Country Status (44)

Country Link
US (5) US9675600B2 (es)
EP (2) EP3590338A3 (es)
JP (3) JP6356907B2 (es)
KR (3) KR101881264B1 (es)
CN (5) CN107375285A (es)
AP (1) AP2017009772A0 (es)
AR (1) AR103118A1 (es)
AU (1) AU2015312231B2 (es)
BR (1) BR112017003552A2 (es)
CA (1) CA2959158A1 (es)
CL (1) CL2017000494A1 (es)
CO (1) CO2017003263A2 (es)
CR (1) CR20170121A (es)
CY (1) CY1122746T1 (es)
DK (1) DK3188599T3 (es)
DO (1) DOP2017000055A (es)
EA (1) EA035578B1 (es)
EC (1) ECSP17019893A (es)
ES (1) ES2761777T3 (es)
GE (1) GEP20186939B (es)
HR (1) HRP20192345T1 (es)
HU (1) HUE046894T2 (es)
IL (1) IL250692B (es)
JO (1) JO3541B1 (es)
LT (1) LT3188599T (es)
MA (1) MA40607B1 (es)
MD (1) MD4710C1 (es)
ME (1) ME03597B (es)
MX (1) MX361741B (es)
MY (1) MY187167A (es)
NI (1) NI201700024A (es)
PE (1) PE20171109A1 (es)
PH (1) PH12017500392B1 (es)
PL (1) PL3188599T3 (es)
PT (1) PT3188599T (es)
RS (1) RS59751B1 (es)
SG (1) SG11201701567UA (es)
SI (1) SI3188599T1 (es)
SV (1) SV2017005400A (es)
TN (1) TN2017000040A1 (es)
TW (1) TWI639429B (es)
UA (1) UA120765C2 (es)
UY (1) UY36286A (es)
WO (1) WO2016036598A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000040A1 (en) 2014-09-04 2018-07-04 Helsinn Healthcare Sa Medical treatments based on anamorelin
WO2020231843A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
CN115569119A (zh) 2019-08-30 2023-01-06 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法
JPWO2021079978A1 (es) 2019-10-24 2021-04-29
TW202327596A (zh) * 2021-09-17 2023-07-16 瑞士商赫爾辛保健公司 於厭食/惡病體質患者針對患者自述結果判定及提供臨床有意義改善之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
EP1660117A2 (en) * 2003-08-06 2006-05-31 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
JP2007531769A (ja) 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
EP1768976B1 (en) * 2004-06-29 2017-04-26 Helsinn Healthcare S.A. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
KR20150020602A (ko) 2012-05-25 2015-02-26 라퀄리아 파마 인코포레이티드 무산증 치료를 위한 그렐린 수용체 효능물질
TN2017000040A1 (en) 2014-09-04 2018-07-04 Helsinn Healthcare Sa Medical treatments based on anamorelin

Also Published As

Publication number Publication date
US20190175574A1 (en) 2019-06-13
US20170296526A1 (en) 2017-10-19
AR103118A1 (es) 2017-04-19
IL250692A0 (en) 2017-04-30
JO3541B1 (ar) 2020-07-05
KR101881264B1 (ko) 2018-07-23
NI201700024A (es) 2017-07-18
MA40607B1 (fr) 2019-11-29
WO2016036598A1 (en) 2016-03-10
HUE046894T2 (hu) 2020-04-28
EP3188599A1 (en) 2017-07-12
CO2017003263A2 (es) 2017-07-28
MY187167A (en) 2021-09-07
ME03597B (me) 2020-07-20
RS59751B1 (sr) 2020-02-28
US20210093627A1 (en) 2021-04-01
AU2015312231A1 (en) 2017-03-23
SI3188599T1 (sl) 2020-02-28
CN109172575A (zh) 2019-01-11
CN107375285A (zh) 2017-11-24
US10278964B2 (en) 2019-05-07
US20160067236A1 (en) 2016-03-10
TN2017000040A1 (en) 2018-07-04
TWI639429B (zh) 2018-11-01
PH12017500392A1 (en) 2017-07-17
SV2017005400A (es) 2017-04-20
MX361741B (es) 2018-12-14
US11723902B2 (en) 2023-08-15
MD4710B1 (ro) 2020-09-30
KR102234319B1 (ko) 2021-04-01
CY1122746T1 (el) 2021-03-12
PH12017500392B1 (en) 2017-07-17
US10894041B2 (en) 2021-01-19
EP3188599B1 (en) 2019-10-02
SG11201701567UA (en) 2017-03-30
KR20170047372A (ko) 2017-05-04
ECSP17019893A (es) 2017-05-31
JP6923486B2 (ja) 2021-08-18
CA2959158A1 (en) 2016-03-10
NZ729673A (en) 2023-09-29
PT3188599T (pt) 2020-01-15
MD4710C1 (ro) 2021-04-30
TW201613587A (en) 2016-04-16
US9675600B2 (en) 2017-06-13
IL250692B (en) 2019-05-30
ES2761777T3 (es) 2020-05-21
EP3590338A3 (en) 2020-03-18
AU2015312231B2 (en) 2017-10-19
LT3188599T (lt) 2019-12-10
AP2017009772A0 (en) 2017-02-28
JP7044918B2 (ja) 2022-03-30
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
US20240024303A1 (en) 2024-01-25
PE20171109A1 (es) 2017-08-07
HRP20192345T1 (hr) 2020-03-20
JP2021080281A (ja) 2021-05-27
MX2017002825A (es) 2017-09-28
CL2017000494A1 (es) 2017-09-15
CN107205389A (zh) 2017-09-26
KR102307275B1 (ko) 2021-09-30
KR20210035923A (ko) 2021-04-01
MD20170025A2 (ro) 2017-07-31
JP6356907B2 (ja) 2018-07-11
CN113577073A (zh) 2021-11-02
KR20180085047A (ko) 2018-07-25
CR20170121A (es) 2017-07-17
UA120765C2 (uk) 2020-02-10
JP2018154655A (ja) 2018-10-04
UY36286A (es) 2016-02-29
JP2017526695A (ja) 2017-09-14
EP3188599A4 (en) 2017-10-11
EP3590338A2 (en) 2020-01-08
CN113577074A (zh) 2021-11-02
PL3188599T3 (pl) 2020-06-01
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
BR112017003552A2 (pt) 2017-12-05

Similar Documents

Publication Publication Date Title
DOP2017000055A (es) Tratamientos médicos a base de anamorelina
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
TWD196868S (zh) 超音波治療手持件
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2021002322A (es) Nuevos metodos.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
ZA202006986B (en) Dantrolene formulations and methods of their use
GT201700041A (es) Tratamientos médicos a base de anamorelina
NZ740722A (en) Oral suspension for treating eosinophilic esophagitis
EA201991866A1 (ru) Комбинированная терапия
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
RU2015109209A (ru) Способ количественной оценки зубочелюстно-лицевых аномалий
CN302490345S (zh) 刺激器
CN302536617S (zh) 高频率治疗仪